# HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness

> **NCT07369622** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Haiphong University of Medicine and Pharmacy** · enrollment: 228 (estimated)

## Conditions studied

- Gout Initiating Urate-loweringUrate-lowering Therapy
- Gout Arthritis
- Gout and Hyperuricemia

## Interventions

- **DIAGNOSTIC_TEST:** HLA-B*58:01 Genotyping
- **DRUG:** Allopurinol Tablet
- **DRUG:** Febuxostat

## Key facts

- **NCT ID:** NCT07369622
- **Lead sponsor:** Haiphong University of Medicine and Pharmacy
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-20
- **Primary completion:** 2027-06-20
- **Final completion:** 2028-12-30
- **Target enrollment:** 228 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07369622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07369622, "HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07369622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*